Mereo BioPharma (MREO) Short term Debt (2017 - 2022)

Mereo BioPharma (MREO) has 4 years of Short term Debt data on file, last reported at $13.0 million in Q4 2022.

• Short term Debt for Q4 2022 came in at $13.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $13.0 million (changed N/A YoY), and the FY2022 annual result was $486000.0, changed N/A from the prior year.
• Short term Debt retreated to $13.0 million in Q4 2022 per MREO's latest filing, from $19.5 million in the prior quarter.
• Over five years, Short term Debt peaked at $19.5 million in Q4 2019 and troughed at $8.8 million in Q4 2018.
• A 3-year average of $13.8 million and a median of $13.0 million in 2022 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2018 and 2019: Short term Debt surged 241.65% in 2018, then surged 121.22% in 2019.
• A 3-year view of Short term Debt shows it stood at $8.8 million in 2018, then jumped by 121.22% to $19.5 million in 2019, then plunged by 33.2% to $13.0 million in 2022.
• Business Quant data shows MREO's Short term Debt at $13.0 million in Q4 2022, $19.5 million in Q4 2019, and $8.8 million in Q4 2018.